Sera Prognostics, Inc. (NASDAQ:SERA) Insider Sells $221,244.96 in Stock

Sera Prognostics, Inc. (NASDAQ:SERA) insider John J. Boniface sold 24,474 shares of the business’s stock in a transaction on Thursday, March 28th. The shares were sold at an average price of $9.04, for a total transaction of $221,244.96. Following the transaction, the insider now owns 139,771 shares in the company, valued at $1,263,529.84. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Sera Prognostics Trading Down 3.8 %

Shares of Sera Prognostics stock traded down $0.36 on Thursday, hitting $9.10. 954,568 shares of the company traded hands, compared to its average volume of 250,452. The company has a 50-day moving average price of $8.40 and a 200 day moving average price of $5.00. Sera Prognostics, Inc. has a 12-month low of $1.52 and a 12-month high of $10.44.

Hedge Funds Weigh In On Sera Prognostics

Institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. boosted its holdings in Sera Prognostics by 4.9% in the first quarter. BlackRock Inc. now owns 186,140 shares of the company’s stock worth $707,000 after purchasing an additional 8,718 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Sera Prognostics by 7.0% in the first quarter. Vanguard Group Inc. now owns 188,127 shares of the company’s stock worth $713,000 after purchasing an additional 12,324 shares in the last quarter. Frontier Wealth Management LLC bought a new stake in Sera Prognostics in the first quarter worth $30,000. Charles Schwab Investment Management Inc. bought a new stake in Sera Prognostics in the first quarter worth $68,000. Finally, Northern Trust Corp boosted its holdings in Sera Prognostics by 54.6% in the first quarter. Northern Trust Corp now owns 56,512 shares of the company’s stock worth $214,000 after purchasing an additional 19,948 shares in the last quarter. 54.64% of the stock is currently owned by hedge funds and other institutional investors.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression.